BR0012984A - Method for treating a condition associated with mc4-r in a mammal, compound binding to mc4-r, and pharmaceutical composition - Google Patents
Method for treating a condition associated with mc4-r in a mammal, compound binding to mc4-r, and pharmaceutical compositionInfo
- Publication number
- BR0012984A BR0012984A BR0012984-4A BR0012984A BR0012984A BR 0012984 A BR0012984 A BR 0012984A BR 0012984 A BR0012984 A BR 0012984A BR 0012984 A BR0012984 A BR 0012984A
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- pharmaceutical composition
- mammal
- condition associated
- compound binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"MéTODO PARA TRATAR UM ESTADO ASSOCIADO COM O MC4-R EM UM MAMìFERO, COMPOSTO DE LIGAçãO AO MC4-R, E, COMPOSIçãO FARMACêUTICA". Os compostos de ligação ao MC4-R da fórmula (I): B-Z-E em que B é uma porção de âncora, Z é uma porção centra e E é uma porção que interage com o MC4-R são debatidos. Os métodos de usar os compostos para tratar distúrbios associados com o MC4-R, tais como os distúrbios associados com a perda de peso, também são debatidos."METHOD FOR TREATING AN STATE ASSOCIATED WITH MC4-R IN A MAMMALIAN, COMPOUND OF CONNECTION TO MC4-R, AND, PHARMACEUTICAL COMPOSITION". The MC4-R binding compounds of formula (I): B-Z-E where B is an anchor portion, Z is a center portion and E is a portion that interacts with MC4-R are discussed. Methods of using the compounds to treat disorders associated with MC4-R, such as disorders associated with weight loss, are also debated.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14728899P | 1999-08-04 | 1999-08-04 | |
US22327700P | 2000-08-03 | 2000-08-03 | |
PCT/US2000/021327 WO2001010842A2 (en) | 1999-08-04 | 2000-08-04 | Melanocortin-4 receptor binding compounds and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0012984A true BR0012984A (en) | 2002-07-16 |
Family
ID=26844785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0012984-4A BR0012984A (en) | 1999-08-04 | 2000-08-04 | Method for treating a condition associated with mc4-r in a mammal, compound binding to mc4-r, and pharmaceutical composition |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1204645A2 (en) |
JP (1) | JP2003528810A (en) |
AU (1) | AU6621600A (en) |
BR (1) | BR0012984A (en) |
CA (1) | CA2381008A1 (en) |
MX (1) | MXPA02001160A (en) |
WO (1) | WO2001010842A2 (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064091A2 (en) | 2001-02-13 | 2002-08-22 | Palatin Technologies, Inc. | Melanocortin metallopeptides for treatment of sexual dysfunction |
US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
JP2003505435A (en) | 1999-06-04 | 2003-02-12 | メルク エンド カムパニー インコーポレーテッド | Substituted piperidines as melanocortin-4 receptor gonists |
US7176279B2 (en) | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
US7375125B2 (en) * | 1999-08-04 | 2008-05-20 | Ore Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
CN1423635A (en) | 2000-04-14 | 2003-06-11 | 吴羽化学工业株式会社 | Nitrogenous compounds and antiviral drugs containing the same |
DZ3415A1 (en) * | 2000-08-31 | 2002-03-07 | Chiron Corp | GUANIDINOBENZAMIDES AS MC4-R AGONISTS. |
AU2001295837A1 (en) * | 2000-10-30 | 2002-05-15 | Warner-Lambert Company Llc | Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis |
WO2002046172A2 (en) * | 2000-12-07 | 2002-06-13 | Cv Therapeutics, Inc. | Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
EP1363890A4 (en) * | 2001-02-07 | 2009-06-10 | Ore Pharmaceuticals Inc | Melanocortin-4 receptor binding compounds and methods of use thereof |
EP1767525A1 (en) | 2001-04-09 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists |
US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
UA81749C2 (en) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Derivated of phenylpiperazine as serotonin reuptake inhibitorS |
US7064139B2 (en) * | 2001-10-29 | 2006-06-20 | Uniroyal Chemical Company, Inc. | Method for treating retroviral infections |
EP1450801A4 (en) * | 2001-11-27 | 2010-10-27 | Merck Sharp & Dohme | 2-aminoquinoline compounds |
JP2005518395A (en) | 2001-12-21 | 2005-06-23 | ハー・ルンドベック・アクチエゼルスカベット | Aminoindane derivatives as inhibitors of serotonin and norepinephrine uptake |
US20030195187A1 (en) * | 2002-02-04 | 2003-10-16 | Chiron Corporation | Guanidino compounds |
WO2003068738A1 (en) * | 2002-02-11 | 2003-08-21 | Neurocrine Biosciences, Inc. | Pyrrole derivatives as ligands of melanocortin receptors |
AU2003223049A1 (en) | 2002-03-13 | 2003-09-22 | Euro-Celtique S.A. | Aryl substituted pyrimidines and the use thereof |
ATE478867T1 (en) | 2002-05-23 | 2010-09-15 | Novartis Vaccines & Diagnostic | SUBSTITUTED QUINAZOLINONE COMPOUNDS |
US7396930B2 (en) | 2002-06-11 | 2008-07-08 | Sankyo Company, Limited | Process for producing cyclic thioether and synthetic intermediate thereof |
AU2003242092A1 (en) * | 2002-06-11 | 2003-12-22 | Sankyo Company, Limited | Process for producing cyclic thioether and synthetic intermediate thereof |
JP2004067673A (en) * | 2002-06-11 | 2004-03-04 | Sankyo Co Ltd | Method for producing cyclic thioether and synthetic intermediate of the same |
GB2389581A (en) * | 2002-06-12 | 2003-12-17 | Viaxxel Biotech Gmbh | Hydrogenated pyrimidines and their use as inhibitors of deoxyhypusine-synthase or hypusination of eIF-5A |
WO2004005324A2 (en) | 2002-07-09 | 2004-01-15 | Palatin Technologies, Inc. | Peptide composition for treatment of sexual dysfunction |
AU2003261974A1 (en) | 2002-09-11 | 2004-04-30 | Kureha Chemical Industry Company, Limited | Amine compounds and use thereof |
EP1558253A4 (en) * | 2002-10-30 | 2007-07-25 | Merck & Co Inc | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity |
US7365070B2 (en) | 2002-12-04 | 2008-04-29 | Ore Pharmaceuticals Inc. | Modulators of melanocortin receptor |
FR2852957B1 (en) * | 2003-03-31 | 2005-06-10 | Sod Conseils Rech Applic | NOVEL IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT |
DK1626720T3 (en) | 2003-04-04 | 2008-12-01 | Lundbeck & Co As H | 4- (2-Phenylsulfanyl-phenyl) -piperidine derivatives as serotonin reuptake inhibitors |
DE10316081A1 (en) * | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | New compounds with antibacterial activity |
AU2004249120B2 (en) | 2003-05-23 | 2008-07-24 | Glaxosmithkline | Guanidino-substituted quinazolinone compounds as MC4-R agonists |
MXPA06005736A (en) | 2003-11-19 | 2006-12-14 | Chiron Corp | Quinazolinone compounds with reduced bioaccumulation. |
FR2862971B1 (en) * | 2003-11-28 | 2006-03-24 | Sod Conseils Rech Applic | NOVEL BENZIMIDAZOLE AND IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT |
MXPA06007172A (en) | 2003-12-23 | 2006-08-23 | Lundbeck & Co As H | 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri. |
CN1950343B (en) | 2004-03-10 | 2013-06-19 | 株式会社吴羽 | Basic amine compound and use thereof |
AR052308A1 (en) | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | DERIVATIVES OF 2- (1H-INDOLILSULFANIL) -ARILAMINE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE COMPOUND |
US20070021433A1 (en) * | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
AR054393A1 (en) | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | DERIVATIVES OF BENZO (B) FURANO AND BENZO (B) THIOPHEN, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE REINFORCEMENT OF AMINA BOSS NEUTRANTS. |
US7629473B2 (en) | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
TW200819426A (en) | 2006-08-31 | 2008-05-01 | Lundbeck & Co As H | Novel indane compounds |
EP2103614A1 (en) * | 2008-03-18 | 2009-09-23 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators |
US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EA020017B1 (en) | 2009-04-30 | 2014-08-29 | Новартис Аг | Imdazole derivatives and their use as modulators of cyclin dependent kinases |
EP2538784B1 (en) | 2010-02-25 | 2015-09-09 | Merck Sharp & Dohme Corp. | Benzimidazole derivatives useful anti-diabetic agents |
EP2677869B1 (en) | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
JP2015525782A (en) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
AU2014211727B2 (en) | 2013-02-04 | 2018-07-26 | Prexton Therapeutics Sa | Positive allosteric modulators of mGluR3 |
CN104994848A (en) | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2016056606A1 (en) * | 2014-10-07 | 2016-04-14 | 国立大学法人京都大学 | Benzoisothiazolopyrimidine derivative and salt thereof,and viral infection inhibitor and drug |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
DK3483164T3 (en) | 2017-03-20 | 2020-03-23 | Forma Therapeutics Inc | PYRROLOPYRROL COMPOSITIONS AS PYRUVAT KINASE (PKR) ACTIVATORS |
CN108084109A (en) * | 2017-12-21 | 2018-05-29 | 南京工业大学 | One kind 2,5- bis- substitutes the synthetic method of -1.3.4- oxadiazoles |
US11666888B2 (en) | 2018-02-05 | 2023-06-06 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
CN112996795A (en) | 2018-09-18 | 2021-06-18 | 尼坎医疗公司 | Fused tricyclic derivatives as SRC homologous-2 phosphatase inhibitors |
WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
WO2020061378A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
JP2022508523A (en) | 2018-10-01 | 2022-01-19 | ジェンザイム・コーポレーション | Thieno [3,2-b] Pyridine Derivatives as UDP Glycosyltransferase Inhibitors and Methods of Use |
TW202322824A (en) | 2020-02-18 | 2023-06-16 | 美商基利科學股份有限公司 | Antiviral compounds |
EP4323362A1 (en) | 2021-04-16 | 2024-02-21 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3594380A (en) * | 1969-02-18 | 1971-07-20 | American Home Prod | Isoquinolin-1(2h)-ones |
DE2219841A1 (en) * | 1972-04-22 | 1973-10-25 | Basf Ag | PROCESS FOR THE PREPARATION OF 2- (OALKYLTHIOPHENYL) -1,3-DIAZACYCLOALKENHYDROHALOGENIDES |
US4122263A (en) * | 1973-04-11 | 1978-10-24 | Basf Aktiengesellschaft | Production of 2-(o-alkylthiophenyl)-1,3-diazocycloalkene hydrohalides |
DE3046366A1 (en) * | 1980-12-09 | 1982-07-08 | Bayer Ag, 5090 Leverkusen | TRICYCLIC CYTOSINE DERIVATIVES FOR USE IN MEDICINAL PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF |
GB8619971D0 (en) * | 1986-08-15 | 1986-09-24 | Fujisawa Pharmaceutical Co | Imidazole compounds |
JPS63253073A (en) * | 1987-04-08 | 1988-10-20 | Taisho Pharmaceut Co Ltd | 2-phenylbenzimidazole derivative |
ZA923283B (en) * | 1991-05-29 | 1993-01-27 | Akzo Nv | Phenoxyphenyl derivatives |
US5731408A (en) * | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
JPH09176871A (en) * | 1995-12-25 | 1997-07-08 | Tamura Kaken Kk | Water soluble pre-flux, printed circuit board and surface treatment of metal of circuit board |
US5932779A (en) * | 1996-06-10 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Screening methods for compounds useful in the regulation of body weight |
CN101239090A (en) * | 1997-04-15 | 2008-08-13 | Csir公司 | Pharmaceutical compositions having appetite suppressant activity |
CA2315226A1 (en) * | 1997-12-19 | 1999-07-01 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
CA2334551A1 (en) * | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
-
2000
- 2000-08-04 EP EP00953837A patent/EP1204645A2/en not_active Withdrawn
- 2000-08-04 WO PCT/US2000/021327 patent/WO2001010842A2/en active Application Filing
- 2000-08-04 JP JP2001515309A patent/JP2003528810A/en active Pending
- 2000-08-04 AU AU66216/00A patent/AU6621600A/en not_active Abandoned
- 2000-08-04 BR BR0012984-4A patent/BR0012984A/en not_active Application Discontinuation
- 2000-08-04 CA CA002381008A patent/CA2381008A1/en not_active Abandoned
- 2000-08-04 MX MXPA02001160A patent/MXPA02001160A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
MXPA02001160A (en) | 2002-07-02 |
JP2003528810A (en) | 2003-09-30 |
EP1204645A2 (en) | 2002-05-15 |
AU6621600A (en) | 2001-03-05 |
CA2381008A1 (en) | 2001-02-15 |
WO2001010842A2 (en) | 2001-02-15 |
WO2001010842A3 (en) | 2001-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0012984A (en) | Method for treating a condition associated with mc4-r in a mammal, compound binding to mc4-r, and pharmaceutical composition | |
EE03869B1 (en) | Sulphinic acid derivatives, their preparation and use | |
BR9808953A (en) | Compound, process to treat a cyclooxygenase-2 mediated disorder in a patient, and pharmaceutical composition | |
BR9908811A (en) | Compound, pharmaceutical composition and its use in the treatment of mammals | |
BR0012136A (en) | Highly selective norepinephrine reabsorption inhibitors and methods of using them | |
BR9811099A (en) | Urokinase inhibitors | |
BR9809147A (en) | Substituted pyrazole compound, pharmaceutical composition, processes for treating a tnf mediated disorder, a p38 kinase mediated disorder, inflammation and arthritis, and for preparing pyrazoles | |
BR0312464A (en) | Tyrosine kinase inhibitors | |
BR9810763A (en) | Absorbent composition for the purification of gases containing acidic components | |
FI972580A (en) | Preparations and methods for reducing skin irritation | |
PT991619E (en) | INHIBITORS OF THE CELLULAR ADHESION MEDIATED BY ALFA4BETA1 | |
BR0114576A (en) | Compound, pharmaceutical composition, use of a compound, method of treating a disease state and process for preparing a compound | |
BR9913592A (en) | Compounds, compound preparation process, and pharmaceutical compositions | |
BR0211251A (en) | Hair and / or scalp composition, shampoo, cosmetic method for hair treatment, dandruff symptom treatment method, method to reduce scalp itching, and, use of a hair-activating agent cb receiver | |
BR9913255A (en) | Compound, pharmaceutical composition, process for treating a metalloproteinase-mediated disease condition, process for preparing a compound, and use of a compound | |
BRPI0515582A (en) | 3- (2-hydroxyphenyl) pyrazoles and their use as hsp90 modulators | |
BR9811948A (en) | Growth hormone secretors | |
BR9914380A (en) | Processes to prevent or treat pruritic vaginal condition in a mammal, and to prevent or treat pruritic condition in the procto-urro-genital areas of a mammal | |
BR9713338A (en) | Benzonaphyridines as bronchial therapeutics. | |
BR0007229A (en) | Substituted heterocyclic aminoazacycles useful as central nervous system agents | |
BR0004535A (en) | Compounds, and, use of them. | |
BR9713159A (en) | Substantially solid composition, compound, substantially solid salt composition, mixture, and, process for preparing a compound | |
BR0110087A (en) | Compounds to modulate cell proliferation | |
BR0012478A (en) | Aminothiazole derivatives, their pharmaceutical preparation and composition containing the same | |
BR0010381A (en) | Method of treating thrombosis in a mammal, and using a combination of (i) a factor xa inhibitor, and (ii) a compound selected from the group consisting of aspirin, tpa, a gpiib / iiia antagonist, low weight heparin molecular and heparin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |